{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:33:48Z","timestamp":1770885228666,"version":"3.50.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009124","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T02:43:10Z","timestamp":1512614590000},"page":"e9124","source":"Crossref","is-referenced-by-count":24,"title":["A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia"],"prefix":"10.1097","volume":"96","author":[{"given":"Xiaoqin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-139-20210226","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1248\/bpb.35.967","article-title":"Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system","volume":"35","author":"Kadoyama","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"R2-139-20210226","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14740338.2015.997206","article-title":"Tigecycline: a critical safety review","volume":"14","author":"Kaewpoowat","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R3-139-20210226","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","article-title":"Pharmacokinetic\/pharmacodynamic profile for tigecycline\u2014a new glycylcycline antimicrobial agent","volume":"52","author":"Meagher","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R4-139-20210226","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0091270010363477","article-title":"Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis","volume":"51","author":"Korth-Bradley","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R5-139-20210226","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00277-010-0911-7","article-title":"Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline","volume":"89","author":"Pieringer","year":"2010","journal-title":"Ann Hematol"},{"key":"R6-139-20210226","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/MEG.0000000000000087","article-title":"Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis","volume":"26","author":"Rossitto","year":"2014","journal-title":"Eur J Gastroen Hepatol"},{"key":"R7-139-20210226","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/23744235.2015.1043942","article-title":"Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder","volume":"47","author":"Sabanis","year":"2015","journal-title":"Infect Dis"},{"key":"R8-139-20210226","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijantimicag.2014.07.014","article-title":"High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections","volume":"45","author":"Routsi","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R9-139-20210226","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0037-1617143","article-title":"The coagulant response in sepsis and inflammation","volume":"30","author":"Levi","year":"2010","journal-title":"Hamostaseologie"},{"key":"R10-139-20210226","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R11-139-20210226","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/AAC.04305-14","article-title":"Tigecycline treatment causes a decrease in fibrinogen levels","volume":"59","author":"Zhang","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:46:37Z","timestamp":1620960397000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712080-00139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":11,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009124","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}